Close

Registration is free and only takes a moment. If you have already registered, please log in now.

Create Account
Forgot your password?
Log In
  • Links
  • Publisher Full Text
  • Authors
  • Fujita T
  • MESH
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Female
  • Humans
  • Receptor, erbB-2
  • Tumor Markers, Biological

Unbound MEDLINE

Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer.

Links

  • Publisher Full Text

    • Authors

    Fujita T

    Source

    Lancet 379:9833 2012 Jun 16 pg 2237; author reply 2238

    MeSH

    Antineoplastic Combined Chemotherapy Protocols
    Breast Neoplasms
    Female
    Humans
    Receptor, erbB-2
    Tumor Markers, Biological

    Pub Type(s)

    Comment
    Letter

    Language

    eng

    PubMed ID

    22704160

    Related Citations

    • Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer.
    • Dual inhibition of HER2 in breast cancer treatment.
    • Anthracyclines in the treatment of HER2-negative breast cancer.
    • Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
    • The effect of neoadjuvant chemotherapy on hormone receptor status, HER2/neu and prolactin in breast cancer.
    • Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    • alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    • Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
    More
    unbound logo
    • Home »
    • Contact Us »
    • Help »
    • Privacy / Disclaimer »
    • Terms of Service »
    • Log In »
    • twitter
    • facebook
    © 2000–2013 Unbound Medicine, Inc. All rights reserved